



April 22, 2024
JCR Pharmaceuticals Co., Ltd.

Translation

JCR Pharmaceuticals Announces Naming Rights Partnership for "Uchibun"

We are excited to announce a heartfelt partnership with Ashiya City to maintain the esteemed name of "Uchibun," covering the Uchide Park and Uchide Educational and Cultural Center. This collaboration, set to last from May 1, 2024, to March 31, 2029, is driven by our shared commitment to honor and cultivate this name that resonates deeply within the community.

"Uchibun" embodies the spirit and the enduring bonds of our community, and we are privileged to be part of its ongoing story.

This partnership aligns with Ashiya City's initiative to enhance the vibrancy and accessibility of its public spaces. The newly reborn "Uchibun" area in April 2024 signifies a recommitment to making this space a beacon for community engagement and enjoyment.

Rooted in Ashiya since the 1990s, we align deeply with the city's aspirations for community development. Our involvement in preserving and enriching "Uchibun" reflects our commitment to contributing to the community's wellbeing.

Our Chairman and President, Shin Ashida says, "I am delighted to collaborate with Ashiya City. "Uchibun" holds a dear place in the hearts of our community, and the responsibility of carrying it forward fills me with great joy."

We look forward to embarking on this journey to further enrich our beloved region.



Overview of Naming Rights

Naming Rights Partner	<ul style="list-style-type: none">· Corporate Name: JCR Pharmaceuticals Co., Ltd.· Headquarters: 3-19, Kasuga-cho, Ashiya city, Hyogo, Japan· Chairman and President: Shin Ashida
Location	Uchide Park, Uchide Educational and Cultural Center (Uchide Branch Library included) <ul style="list-style-type: none">· 5-3, Uchidekozuchi-cho, Ashiya city, Hyogo, Japan· 15-9, Uchidekozuchi-cho, Ashiya city, Hyogo, Japan
Name	Uchibun
Term	May 1, 2024, to March 31, 2029

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###